EXPAND DEFINITION OF OPIOID ANTAGONIST.

Printer-friendly: Click to view
View NCGA Bill Details(link is external)2023-2024 Session
House Bill 35 (Public) Filed Monday, January 30, 2023
AN ACT EXPANDING THE STATE'S DEFINITION OF OPIOID ANTAGONIST TO INCLUDE ALL OPIOID ANTAGONISTS APPROVED BY THE FEDERAL FOOD AND DRUG ADMINISTRATION FOR THE TREATMENT OF A DRUG OVERDOSE; AND TO ALLOW THE USE OF ALL SUCH FEDERAL FOOD AND DRUG-APPROVED OPIOID ANTAGONISTS IN NEEDLE AND HYPODERMIC SYRINGE EXCHANGE PROGRAMS.
Intro. by Sasser, Potts, Lambeth, Paré.
Status: Ref To Com On Rules and Operations of the Senate (Senate action) (Feb 27 2023)

Bill History:

H 35

Bill Summaries:

  • Bill H 35 (2023-2024)
    Summary date: Jan 30 2023 - View Summary

    As title indicates, amends GS 90-12.7(a) to change the definition of opioid antagonist from naloxone hydrochloride that is approved by the FDA for treatment of a drug overdoes to an opioid antagonist that is approved by the FDA for treatment of a drug overdose. Makes conforming changes to GS 90-113.27 by requiring that needle and hypodermic syringe exchange programs offer access to opioid antagonist (was, naloxone) kits that contain an opioid antagonist approved by FDA for the treatment of a drug overdose, or referrals to programs providing access to an opioid antagonist that is approved by the FDA for the treatment of a drug overdose. Makes additional conforming changes.

    Health and Human Services, Health, Public Health
    GS 90
View: All Summaries for Bill